NVS Jan 2025 110.000 put
| Previous close | 14.10 |
| Open | 14.20 |
| Bid | 14.90 |
| Ask | 18.90 |
| Strike | 110.00 |
| Expiry date | 2025-01-17 |
| Day's range | 14.10 - 14.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
ZacksNovartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.
GlobeNewswireNew Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide2; complement activation is a key driver of glomerular inflammation in IgAN3,4There is a need for effective, targeted therapies for IgAN2,5; up to 30% of patients with persistent proteinuria (≥1 g/day) may progress to kidney failure
Yahoo FinanceAntitrust fervor is gripping Washington and Silicon Valley. But lawsuits have been declining.
Antitrust lawsuits have declined since the pandemic despite a high-profile push by Washington to limit the concentration of power in key industries.
